Most Read Articles
Natalia Reoutova, 2 days ago

A retrospective analysis of seven clinical trials demonstrated that neratinib-based therapy is safe and effective in Asian patients with metastatic HER2-positive breast cancer.

Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Pearl Toh, 28 Aug 2019
The addition of radium-223 (Ra223) to enzalutamide for the treatment of mCRPC* was associated with increased fracture risk, which was entirely abolished with mandated use of bone-protecting agents (BPAs) such as zoledronic acid and denosumab, according to interim results of the EORTC 1333 (PEACE III) trial.
Audrey Abella, 28 Aug 2019
A pooled analysis of six trials failed to show noninferiority of a 3-month regimen to a 6-month regimen of oxaliplatin-based chemotherapy for patients with high-risk, stage II colorectal cancer (CRC).

Positive post-treatment biopsy after radiotherapy tied to higher risk of distant metastasis, death

29 May 2019

Patients with a positive post-treatment biopsy after external beam radiotherapy are at higher risk of distant metastasis and prostate cancer-related death, suggests a recent study. Positive post-treatment biopsies are more frequent in the setting of external beam radiotherapy alone without androgen deprivation therapy or in the presence of high-risk disease.

“Patients with severe treatment effect classified biopsies have biological characteristics more like patients with a negative biopsy than a positive biopsy,” the investigators said.

Positive biopsy had a 30-percent prevalence, while treatment effect and negative biopsy had a rate of 22 percent and 48 percent, respectively. Androgen deprivation therapy omission and high-risk disease correlated with a 2.6- and 1.8-fold increase in the odds of positive post-treatment biopsy.

For prostate-specific antigen (PSA), the 15-year relapse rate associated with negative, severe treatment effect and positive post-treatment biopsies were 34 percent, 36 percent and 79 percent, respectively (p<0.001).

Distant metastasis was 2.6 times more likely to occur and cause-specific mortality was twice as high in patients with a positive biopsy (p<0.001) compared to those with negative and severe treatment effect biopsy outcomes (hazard ratio, 2.00; p=0.022) after controlling for known predictors.

This study included 382 patients who underwent a post-treatment biopsy after external beam radiotherapy for clinically localized prostate cancer. Post-treatment biopsies were categorized as positive (prostatic adenocarcinoma without typical radiation induced changes), negative (no evidence of carcinoma) or adenocarcinoma with a severe treatment effect. Median follow-up was 9 years.

The investigators examined associations between prognostic predictors and cause-specific mortality, distant metastasis and PSA failure using competing risks regression.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 2 days ago

A retrospective analysis of seven clinical trials demonstrated that neratinib-based therapy is safe and effective in Asian patients with metastatic HER2-positive breast cancer.

Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Pearl Toh, 28 Aug 2019
The addition of radium-223 (Ra223) to enzalutamide for the treatment of mCRPC* was associated with increased fracture risk, which was entirely abolished with mandated use of bone-protecting agents (BPAs) such as zoledronic acid and denosumab, according to interim results of the EORTC 1333 (PEACE III) trial.
Audrey Abella, 28 Aug 2019
A pooled analysis of six trials failed to show noninferiority of a 3-month regimen to a 6-month regimen of oxaliplatin-based chemotherapy for patients with high-risk, stage II colorectal cancer (CRC).